Agendia to Unveil New Findings in Early-Stage Breast Cancer at San Antonio Breast Cancer Symposium 2024

New data reinforces MammaPrint® and BluePrint® tests’ expanding clinical Read More

2025-04-17T13:46:07-04:00November 25th, 2024|Press Releases|

Agendia Co-Founder Prof. Dr. Laura van’t Veer Honored at Three Prestigious Breast Cancer Symposia in Italy, the Netherlands and the U.S. for Pioneering Work in Breast Cancer Diagnostics

IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS, November 14, 2024 Read More

2025-04-17T13:47:06-04:00November 14th, 2024|Press Releases|

Agendia’s FLEX Study Reaches Enrollment of Over 17,000 Early-Stage Breast Cancer Patients Across Diverse Population

This achievement highlights the remarkable seven-year progression of FLEX Read More

2025-04-17T13:48:18-04:00September 12th, 2024|Press Releases|

MammaPrint & 3-year outcome of CT with/without anthracycline-ASCO 2024

Association of MammaPrint index and 3-year outcome of patients in the FLEX Registry trial with HR+HER2- early-stage breast cancer treated with chemotherapy with or without anthracycline

Read More
2025-05-06T14:53:23-04:00May 31st, 2024|Press Releases|

Agendia Announces New I-SPY2 Data Showcasing Ability of New Signature ImPrintTN

Agendia Announces New Data from I-SPY 2 Showcasing Ability of New Signature ImPrintTN to Predict Immunotherapy Response in Patients with Triple Negative Breast Cancer

Read More
2025-05-06T15:22:15-04:00March 20th, 2024|Press Releases|
Go to Top